Samsung Biologics' second-quarter revenue grew 30% year on year to KRW 1.32 trillion, driven by full utilization of its plants. It also announced the acquisition of PolyPeptide, expected to close by year-end. Operating margin fell 270 basis points due to greater depreciation costs.
Samsung Biologics has the flexibility to increase capacity through acquisitions, allowing it to immediately capture more demand and boost revenue growth.
A centralized supply chain could backfire if disruptions occur at its main Korean site, jeopardizing its reputation and client contracts.
|
Metric
|
207940
|
02269
|
CRL
|
|---|---|---|---|
Price/Earnings (Normalized) | 42.44 | 35.59 | 28.97 |
Price/Book Value | 7.87 | 4.35 | 4.82 |
Price/Sales | 14.57 | 8.87 | 3.50 |
Price/Cash Flow | 26.09 | 24.07 | 20.40 |
|
Metric
|
207940
|
02269
|
CRL
|
|---|---|---|---|
Quick Ratio | 1.00 | 2.64 | 0.80 |
Current Ratio | 1.80 | 3.32 | 1.35 |
Interest Coverage | 75.09 | 67.52 | −0.77 |
|
Metric
|
207940
|
02269
|
CRL
|
|---|---|---|---|
Return on Assets (Normalized) | 13.22% | 10.38% | 6.50% |
Return on Equity (Normalized) | 20.01% | 14.65% | 15.51% |
Return on Invested Capital (Normalized) | 17.55% | 11.25% | 9.46% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$%bj>S& | LOCK|Wf?rt | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|H!#<H< | LOCK|%<@@X | $76B | |||
| Moderna Inc
MRNA
| LOCK|w!zM#l | LOCK|dRT | $75B | |||
| argenx SE ADR
ARGX
| LOCK|?RS#&p | LOCK|X< | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k<$rK@@ | LOCK|bn | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|f&B#Zy | LOCK|d#tHv | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|cr&&BDR> | LOCK|fPD% | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|xVGGnC | LOCK|Q> | $24B | |||
| Incyte Corp
INCY
| LOCK|!LvwYT | LOCK|n$! | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$q%!!&f | LOCK|gnr | $15B |
United States